Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (12986)	8/10/1998 7:21:00 PM
From: VLAD	Read Replies (2) \| Respond to of 23519

One other positive point I would like to add. Although Invamed is not considered a brokerage powerhouse, they are well respected for their knowledge and research of the biotech industry. As a market maker they will tend to represent client that are "in the know" regarding the inner workings of where this company is heading. I believe that they were the ones who were buying shares for Vivus back in February at $15.00/share. I do not know who is using them to buy shares of Vivus but I suspect someone or some fund feels that 5 3/4 is not only a good entry point to buy based on technical support, but also is a good price to buy shares based on the future outlook of the company.